CA3148400A1 - Use of sotagliflozin for the treatment of patients with type 2 diabetes mellitus and moderate renal impairment - Google Patents

Use of sotagliflozin for the treatment of patients with type 2 diabetes mellitus and moderate renal impairment Download PDF

Info

Publication number
CA3148400A1
CA3148400A1 CA3148400A CA3148400A CA3148400A1 CA 3148400 A1 CA3148400 A1 CA 3148400A1 CA 3148400 A CA3148400 A CA 3148400A CA 3148400 A CA3148400 A CA 3148400A CA 3148400 A1 CA3148400 A1 CA 3148400A1
Authority
CA
Canada
Prior art keywords
sotagliflozin
patients
dose
type
diabetes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3148400A
Other languages
English (en)
French (fr)
Inventor
David Bregman
Ali Hariri
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lexicon Pharmaceuticals Inc
Original Assignee
Lexicon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lexicon Pharmaceuticals Inc filed Critical Lexicon Pharmaceuticals Inc
Publication of CA3148400A1 publication Critical patent/CA3148400A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3148400A 2019-07-25 2020-07-24 Use of sotagliflozin for the treatment of patients with type 2 diabetes mellitus and moderate renal impairment Pending CA3148400A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19188477.4A EP3769767A1 (en) 2019-07-25 2019-07-25 Use of sotagliflozin for the treatment of patients with type 2 diabetes mellitus and moderate renal impairment
EP19188477.4 2019-07-25
PCT/IB2020/057016 WO2021014420A1 (en) 2019-07-25 2020-07-24 Use of sotagliflozin for the treatment of patients with type 2 diabetes mellitus and moderate renal impairment

Publications (1)

Publication Number Publication Date
CA3148400A1 true CA3148400A1 (en) 2021-01-28

Family

ID=67438963

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3148400A Pending CA3148400A1 (en) 2019-07-25 2020-07-24 Use of sotagliflozin for the treatment of patients with type 2 diabetes mellitus and moderate renal impairment

Country Status (7)

Country Link
US (1) US20220265690A1 (enExample)
EP (2) EP3769767A1 (enExample)
JP (1) JP2022541322A (enExample)
CN (1) CN114222571A (enExample)
AU (1) AU2020319164A1 (enExample)
CA (1) CA3148400A1 (enExample)
WO (1) WO2021014420A1 (enExample)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008010959A2 (en) 2006-07-14 2008-01-24 The Trustees Of The University Of Pennsylvania Beam ablation lithography

Also Published As

Publication number Publication date
CN114222571A (zh) 2022-03-22
WO2021014420A1 (en) 2021-01-28
EP4003366A1 (en) 2022-06-01
US20220265690A1 (en) 2022-08-25
JP2022541322A (ja) 2022-09-22
EP3769767A1 (en) 2021-01-27
AU2020319164A1 (en) 2022-02-24

Similar Documents

Publication Publication Date Title
Danne et al. HbA1c and hypoglycemia reductions at 24 and 52 weeks with sotagliflozin in combination with insulin in adults with type 1 diabetes: the European inTandem2 study
Landgraf et al. Therapy of type 2 diabetes
DeFronzo et al. Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin
Matthaei et al. Randomized, double-blind trial of triple therapy with saxagliptin add-on to dapagliflozin plus metformin in patients with type 2 diabetes
Allegaert et al. Developmental pharmacokinetics in neonates: maturational changes and beyond
AU2024205251A1 (en) Dosing regimens for the treatment of fabry disease
AU2012328388B2 (en) Treatment protocol of diabetes type 2
Zakaraia et al. Adding empagliflozin to sitagliptin plus metformin vs. adding sitagliptin to empagliflozin plus metformin as triple therapy in Egyptian patients with type 2 diabetes: a 12-week open trial.
Shestakova et al. Efficacy and safety of luseogliflozin in Caucasian patients with type 2 diabetes: results from a phase III, randomized, placebo-controlled, clinical trial
Sosale et al. A prospective analysis of the efficacy and safety of sodium glucose cotransporter 2 inhibitors: real world evidence from clinical practice in India
Powell et al. Sodium-glucose cotransporter 2 inhibitors: the new option for diabetes mellitus management
AU2020319164A1 (en) Use of sotagliflozin for the treatment of patients with type 2 diabetes mellitus and moderate renal impairment
Karyekar et al. Efficacy and safety of saxagliptin combination therapy in US patients with type 2 diabetes
Bellomo Damato et al. Nateglinide provides tighter glycaemic control than glyburide in patients with Type 2 diabetes with prevalent postprandial hyperglycaemia
HK40062957A (en) Use of sotagliflozin for the treatment of patients with type 2 diabetes mellitus and moderate renal impairment
JP7482146B2 (ja) １型真性糖尿病を有する患者の治療のためのソタグリフロジンの使用
US11045538B2 (en) Method and composition for treatment of hyperglycemia
Sharma Section 8: Diabetes Care in Special Populations
Miller et al. Role of the Kidney and SGLT-2 Inhibition in Type 2 Diabetes Mellitus.
Gupta 25 Intensive Glycemic Control: Is it
KHAN The Effect of Bergenia ligulata WALL in prediabetes: A randomized single-blind placebo-controlled study.
Hosein et al. Canagliflozin: A First-in-Class Medication for the Treatment of Type 2 Diabetes Mellitus
HK40036814A (en) Dosing regimens for the treatment of fabry disease
WARD et al. Efficacy and Safety of Recombinant Human Activated Protein C for Severe Sepsis
Elliott et al. Empagliflozin Tablets (Jardiance®)

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220817